Goodwill And Intangible Assets (Schedule Of Company's Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		12 Months Ended
	Jan. 31, 2015		Nov. 01, 2014
Finite-Lived Intangible Assets
Gross Carrying Value	$ 22,310		$ 14,560
Accumulated Amortization	3,787		3,012
Net Carrying Value	18,523	[1]	11,548	[1]
Weighted- Average Remaining Useful Life (in years)	10 years 1 month 6 days		4 years 1 month 6 days
Trade name
Finite-Lived Intangible Assets
Gross Carrying Value	590		590
Accumulated Amortization	262		227
Net Carrying Value	328		363
Weighted- Average Remaining Useful Life (in years)	2 years 9 months 18 days		3 years 0 months 0 days
Core/developed technology
Finite-Lived Intangible Assets
Gross Carrying Value	12,080		12,080
Accumulated Amortization	2,602		1,964
Net Carrying Value	9,478		10,116
Weighted- Average Remaining Useful Life (in years)	4 years 0 months 25 days		4 years 3 months 18 days
Patent license (1)
Finite-Lived Intangible Assets
Gross Carrying Value	7,750	[2]
Accumulated Amortization	0	[2]
Net Carrying Value	7,750	[2]
Weighted- Average Remaining Useful Life (in years)	18 years 8 months 26 days	[2]
Customer relationships
Finite-Lived Intangible Assets
Gross Carrying Value	1,080		1,080
Accumulated Amortization	479		427
Net Carrying Value	601		653
Weighted- Average Remaining Useful Life (in years)	2 years 9 months 4 days		3 years 0 months 4 days
Non-compete agreements
Finite-Lived Intangible Assets
Gross Carrying Value	810		810
Accumulated Amortization	444		394
Net Carrying Value	$ 366		$ 416
Weighted- Average Remaining Useful Life (in years)	1 year 9 months 4 days		2 years 0 months 4 days

[1] During the three months ended January 31, 2015, the Company purchased a perpetual, non-exclusive license to certain patents for $7.8 million.

[2] The patent license was assigned an estimated useful life that reflects the Company’s consumption of the expected defensive benefits related to this intangible asset. The method of amortization for the patent license reflects the Company’s estimate of the pattern in which these expected defensive benefits will be consumed or otherwise used up by the Company, and is primarily driven by a mix of expiration patterns of the individual patents included in the license.